[13C5]-Pralatrexate

[13C5]-Pralatrexate is a stable isotope-labeled form of Pralatrexate, a folate analogue that is used as an antineoplastic agent. Pralatrexate is a dihydrofolate reductase inhibitor, which means that it interferes with DNA synthesis, thereby preventing the proliferation of cancer cells. It is primarily used to treat peripheral T-cell lymphoma (PTCL), a rare and aggressive type of non-Hodgkin lymphoma. [13C5]-Pralatrexate is used in scientific research to study the pharmacokinetics and metabolism of Pralatrexate in vivo. It is administered orally or intravenously and is metabolized primarily in the liver. The stable isotope-labeled form of the drug allows researchers to track the drug's metabolism and distribution in the body using sophisticated analytical techniques like mass spectrometry. The chemical formula of [13C5]-Pralatrexate is C23H20N8O5, and it has a molecular weight of 484.46 g/mol. It is a white to off-white powder that is soluble in water, methanol, and dimethyl sulfoxide. Like other antineoplastic agents, [13C5]-Pralatrexate can cause side effects such as nausea, vomiting, diarrhea, fatigue, and decreased appetite. It is important to handle this drug with care as it can be harmful if ingested or inhaled. Overall, [13C5]-Pralatrexate plays a crucial role in advancing our understanding of Pralatrexate's pharmacology, which may ultimately lead to improved treatments for cancer patients.